Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 1999 June;43(2) > The Quarterly Journal of Nuclear Medicine 1999 June;43(2):159-62

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 1999 June;43(2):159-62

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Vascular targeting with phage peptide libraries

Pasqualini R.

From the La Jolla Cancer Research Center The Burnham Institute, La Jolla, CA (USA)


PDF


We ­have devel­oped an in ­vivo selec­tion ­system in ­which ­phage ­capable of selec­tive hom­ing to dif­fer­ent tis­sues are recov­ered ­from a ­phage dis­play pep­tide ­library fol­low­ing intra­ve­nous admin­is­tra­tion. Using ­this strat­e­gy, we ­have iso­lat­ed sev­er­al ­organ and ­tumor-hom­ing pep­tides. We ­have ­shown ­that ­each of ­those pep­tides ­binds to dif­fer­ent recep­tors ­that are selec­tive­ly ­expressed on the vas­cu­la­ture of the tar­get tis­sue. The ­tumor-hom­ing pep­tides ­bind to recep­tors ­that are upreg­u­lat­ed in ­tumor angio­gen­ic vas­cu­la­ture. Targeted deliv­ery of dox­o­ru­bi­cin to angio­gen­ic vas­cu­la­ture ­using ­these pep­tides in ani­mal mod­els ­decreased tox­ic­ity and ­increased the ther­a­peu­tic effi­ca­cy of the ­drug. Vascular tar­get­ing may facil­i­tate the devel­op­ment of oth­er treat­ment strat­e­gies ­that ­rely on inhi­bi­tion of angio­gen­e­sis and ­lead to advanc­es in can­cer treat­ment. Our tech­nol­o­gy is ­also like­ly to ­extend the poten­tial for tar­get­ing of ­drugs, ­genes, and radio­nu­clides in the con­text of ­many dis­eas­es.

top of page